Fate Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FATE research report →
Companywww.fatetherapeutics.com
Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
- CEO
- Bahram Valamehr
- IPO
- 2013
- Employees
- 181
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $214.47M
- P/E
- -1.70
- P/S
- 33.96
- P/B
- 1.23
- EV/EBITDA
- -2.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 53.80%
- Op Margin
- -2207.47%
- Net Margin
- -2056.79%
- ROE
- -58.89%
- ROIC
- -53.84%
Growth & Income
- Revenue
- $6.65M · -51.24%
- Net Income
- $-136,315,000 · 26.82%
- EPS
- $-1.15 · 29.88%
- Op Income
- $-147,704,000
- FCF YoY
- 9.36%
Performance & Tape
- 52W High
- $2.47
- 52W Low
- $0.91
- 50D MA
- $1.45
- 200D MA
- $1.24
- Beta
- 2.14
- Avg Volume
- 2.15M
Get TickerSpark's AI analysis on FATE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 6, 26 | TAHL CINDY | other | 44,444 |
| May 6, 26 | TAHL CINDY | other | 122,220 |
| May 6, 26 | TAHL CINDY | other | 44,444 |
| May 6, 26 | TAHL CINDY | other | 122,220 |
| May 5, 26 | EPSTEIN ROBERT S | other | 25,000 |
| May 5, 26 | EPSTEIN ROBERT S | other | 25,000 |
| May 5, 26 | RASTETTER WILLIAM H | other | 25,000 |
| May 5, 26 | RASTETTER WILLIAM H | other | 25,000 |
| Apr 20, 26 | Redmile Group, LLC | other | 266,280 |
| Apr 20, 26 | Redmile Group, LLC | other | 266,280 |
Our FATE Coverage
We haven't published any research on FATE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FATE Report →